Hong Kong’s Innovation Drug ETF (513120) has seen explosive trading activity, with daily turnover surpassing 13 billion yuan and the fund gaining 3.71% intraday. The ETF has recorded remarkable three-day inflows totaling 13.011 billion yuan, representing a 91.11% surge from yesterday’s levels at the same time.
Despite its strong liquidity, the fund’s share count has decreased by 2.718 billion (22.95%) over the past month, suggesting potential consolidation or redemption activity. The ETF’s T+0 trading feature has contributed to its heightened volatility and appeal among short-term traders.
This surge reflects growing investor interest in Hong Kong’s biotech sector, particularly innovative drug developers, as market sentiment improves toward high-growth healthcare stocks. The fund’s performance highlights both speculative trading activity and renewed confidence in the sector’s long-term prospects.
Related topics：
